MARKET

FDMT

FDMT

4D Molecular Therapeutics Inc.
NASDAQ
10.14
+0.21
+2.11%
After Hours: 10.14 0 0.00% 19:46 05/08 EDT
OPEN
9.08
PREV CLOSE
9.93
HIGH
10.16
LOW
9.06
VOLUME
832.11K
TURNOVER
--
52 WEEK HIGH
12.34
52 WEEK LOW
3.000
MARKET CAP
530.07M
P/E (TTM)
-3.7592
1D
5D
1M
3M
1Y
5Y
1D
Daniel Giraldo Reiterates Buy on 4D Molecular Therapeutics, Citing Strong 4D-150 Progress and Undervalued Upside vs. $29 Price Target
TipRanks · 6h ago
Analysts Offer Insights on Healthcare Companies: Rockwell Med (RMTI), 4D Molecular Therapeutics (FDMT) and Cognition Therapeutics (CGTX)
TipRanks · 2d ago
RBC Capital Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT)
TipRanks · 2d ago
4D Molecular price target lowered to $33 from $38 at Goldman Sachs
TipRanks · 2d ago
4D Molecular files $400M mixed securities shelf
TipRanks · 2d ago
4D Molecular reports Q1 EPS ($1.01), consensus ($1.00)
TipRanks · 2d ago
4D Molecular Therapeutics Files Prospectus To Offer And Sell Up To $400M Of Securities In Multiple Offerings
Benzinga · 2d ago
4D MOLECULAR THERAPEUTICS INC - MAY OFFER AND SELL UP TO $400 MLN OF SECURITIES IN MULTIPLE OFFERINGS - SEC FILING
Reuters · 2d ago
More
About FDMT
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.

Webull offers 4D Molecular Therapeutics Inc stock information, including NASDAQ: FDMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FDMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FDMT stock methods without spending real money on the virtual paper trading platform.